New implant aims to tame glaucoma with one dose
NCT ID NCT05822245
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new implant called PER-001 placed inside the eye to treat open-angle glaucoma. The trial included 33 adults and checked for safety and how well it controlled eye pressure. The implant is designed to release medication over time, potentially reducing the need for daily eye drops.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PER-001 intravitreal implant
What this could lead to
If successful, this implant could offer a new way to lower eye pressure and help control glaucoma with a single dose.
What could go wrong
This is an early-phase trial with only 33 people, so safety and effectiveness are not yet proven. The implant may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPEN ANGLE GLAUCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Perfuse Therapeutics, Inc.
San Francisco, California, 94158, United States